Becton, Dickinson and Company

NYSE:BDX 株式レポート

時価総額:US$67.5b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Becton Dickinson マネジメント

マネジメント 基準チェック /44

Becton Dickinson'sの CEO はTom Polenで、 Apr2017年に任命され、 の在任期間は 7.17年です。 の年間総報酬は$ 17.31Mで、 7.6%給与と92.4%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.02%を直接所有しており、その価値は$ 13.84M 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と6.6年です。

主要情報

Tom Polen

最高経営責任者

US$17.3m

報酬総額

CEO給与比率7.6%
CEO在任期間7.2yrs
CEOの所有権0.02%
経営陣の平均在職期間2.6yrs
取締役会の平均在任期間6.6yrs

経営陣の近況

Recent updates

Is Becton Dickinson (NYSE:BDX) Using Too Much Debt?

May 24
Is Becton Dickinson (NYSE:BDX) Using Too Much Debt?

Becton, Dickinson and Company: Stagnating All Along

May 16

Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)

Mar 23
Investors Still Waiting For A Pull Back In Becton, Dickinson and Company (NYSE:BDX)

Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)

Feb 29
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX)

Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Feb 08
Becton Dickinson's (NYSE:BDX) Conservative Accounting Might Explain Soft Earnings

Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Feb 03
Becton, Dickinson and Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Feb 01
These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Becton, Dickinson: 4 Reasons To Buy This Growth At A Reasonable Price Play

Jan 22

Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 30
Becton Dickinson's (NYSE:BDX) Shareholders Will Receive A Bigger Dividend Than Last Year

Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24

Nov 13

Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's

Nov 12
Becton Dickinson's (NYSE:BDX) Upcoming Dividend Will Be Larger Than Last Year's

Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price

Nov 06
Becton, Dickinson and Company's (NYSE:BDX) Intrinsic Value Is Potentially 26% Above Its Share Price

With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case

Oct 05
With EPS Growth And More, Becton Dickinson (NYSE:BDX) Makes An Interesting Case

Becton, Dickinson Stock Is A Hold, Here's Why

Oct 04

Becton, Dickinson: Ahead Of Schedule, Undervalued, And With Some Positive Drivers

Aug 30

We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Aug 13
We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Jul 28
Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching

Jun 22
Here's Why We Think Becton Dickinson (NYSE:BDX) Is Well Worth Watching

Becton, Dickinson and Company: Still Not Very Healthy

Jun 20

Becton, Dickinson: Business Should Beat H2 2023 Expectations

Jun 08

These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Apr 22
These 4 Measures Indicate That Becton Dickinson (NYSE:BDX) Is Using Debt Reasonably Well

Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?

Mar 20
Is Now The Time To Put Becton Dickinson (NYSE:BDX) On Your Watchlist?

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Mar 05
Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson HPV test Onclarity gets FDA nod for expanded use

Feb 21

Becton, Dickinson wins FDA nod for flu, COVID, RSV combo test

Feb 08

Becton, Dickinson Q1 2023 Earnings Preview

Feb 01

Becton, Dickinson declares $0.91 dividend

Jan 24

We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

Jan 09
We Think Becton Dickinson (NYSE:BDX) Can Stay On Top Of Its Debt

CerTest/Becton, Dickinson's test for monkeypox gets FDA emergency use nod

Jan 09

Becton, Dickinson: A Quality Defensive Pick For 2023

Dec 20

Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Dec 01
Estimating The Intrinsic Value Of Becton, Dickinson and Company (NYSE:BDX)

Becton Dickinson (NYSE:BDX) Is Increasing Its Dividend To $0.91

Nov 13
Becton Dickinson (NYSE:BDX) Is Increasing Its Dividend To $0.91

Becton, Dickinson Q4 2022 Earnings Preview

Nov 09

Becton, Dickinson, Biocorp team up for traceability of injectable drugs

Oct 18

CEO報酬分析

Becton Dickinson の収益と比較して、Tom Polen の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

US$1b

Dec 31 2023n/an/a

US$1b

Sep 30 2023US$17mUS$1m

US$1b

Jun 30 2023n/an/a

US$2b

Mar 31 2023n/an/a

US$2b

Dec 31 2022n/an/a

US$1b

Sep 30 2022US$17mUS$1m

US$2b

Jun 30 2022n/an/a

US$1b

Mar 31 2022n/an/a

US$1b

Dec 31 2021n/an/a

US$1b

Sep 30 2021US$14mUS$1m

US$2b

Jun 30 2021n/an/a

US$1b

Mar 31 2021n/an/a

US$1b

Dec 31 2020n/an/a

US$2b

Sep 30 2020US$12mUS$952k

US$245m

Jun 30 2020n/an/a

US$786m

Mar 31 2020n/an/a

US$923m

Dec 31 2019n/an/a

US$760m

Sep 30 2019US$6mUS$900k

US$1b

Jun 30 2019n/an/a

US$784m

Mar 31 2019n/an/a

US$926m

Dec 31 2018n/an/a

US$894m

Sep 30 2018US$6mUS$850k

US$159m

Jun 30 2018n/an/a

US$621m

Mar 31 2018n/an/a

-US$99m

Dec 31 2017n/an/a

US$294m

Sep 30 2017US$4mUS$761k

US$1b

報酬と市場: Tomの 総報酬 ($USD 17.31M ) は、 US市場 ($USD 13.55M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Tomの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Tom Polen (51 yo)

7.2yrs

在職期間

US$17,309,938

報酬

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been Director at Walgreens Boots Alliance,...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Thomas Polen
President7.2yrsUS$17.31m0.020%
$ 13.8m
Christopher DelOrefice
Executive VP & CFO2.8yrsUS$5.21m0.0014%
$ 959.2k
Shana Neal
Executive VP & Chief People Officer2.2yrsUS$5.89m0.0057%
$ 3.8m
David Hickey
Executive VP & President of Life Sciences Segment3.4yrsUS$3.35m0.0043%
$ 2.9m
Michael Garrison
Executive VP & President of Medical segment1.8yrsUS$3.65m0.0019%
$ 1.3m
Thomas Spoerel
Senior VP4.7yrsデータなし0.00072%
$ 486.4k
Elizabeth McCombs
Executive VP & Chief Technology Officer3.2yrsデータなしデータなし
Joseph Smith
Senior VP2.6yrsデータなしデータなし
Denise Fleming
Executive VP of Technology & Global Services and Chief Information Officer2.4yrsデータなしデータなし
Greg Rodetis
Head of Investor Relationsless than a yearデータなしデータなし
Michelle Quinn
Executive VP & General Counsel1.3yrsデータなし0.0017%
$ 1.2m
Claudia Curtis
Senior VPno dataデータなしデータなし

2.6yrs

平均在職期間

54yo

平均年齢

経験豊富な経営陣: BDXの経営陣は 経験豊富 であると考えられます ( 2.6年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Thomas Polen
President4.4yrsUS$17.31m0.020%
$ 13.8m
Joseph Smith
Senior VP2.6yrsデータなしデータなし
John DeFord
Co-Chair of Scientific Advisory Board3.1yrsデータなしデータなし
Robert Eckert
Independent Director7.8yrsUS$362.77k0.0028%
$ 1.9m
Timothy Ring
Independent Director7.4yrsUS$332.78k0.020%
$ 13.8m
Jeffrey Henderson
Independent Director5.8yrsUS$357.78k0.0019%
$ 1.3m
Christopher Ian Jones
Independent Director13.9yrsUS$362.78k0.0074%
$ 5.0m
Bertram Scott
Lead Independent Director21.8yrsUS$372.78k0.012%
$ 8.2m
Catherine Burzik
Independent Director11.4yrsUS$357.78k0.0046%
$ 3.1m
William Brown
Independent Director2.3yrsUS$332.78k0.00087%
$ 587.7k
Claire Fraser-Liggett
Member of Scientific Advisory Board & Independent Director17.6yrsUS$340.15k0.0078%
$ 5.3m
Carrie Byington
Independent Director2.7yrsUS$337.78k0.00099%
$ 668.7k

6.6yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: BDXの 取締役会経験豊富 であると考えられます ( 6.6年の平均在任期間)。